T

Tampere University Hospital | Tampere Heart Hospital

Research site
(Unclaimed)
Location
Elamanaukio 1, Tampere, Pirkanmaa, Finland
Site insights

Top conditions

Prostatic Cancer (24 trials)

Wounds and Injuries (17 trials)

Hemorrhage (11 trials)

Bone Fractures (11 trials)

Postoperative Pain (10 trials)

Top treatments

Lenalidomide
Nintedanib
Carboplatin
Upadacitinib
Temozolomide
Interferon
ABT-494
Docetaxel
BI 1015550
Doxorubicin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

41 of 347
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: rituximab
Drug: placebo

The drug that will be investigated in the study is an antibody, epcoritamab, also known as EPKINLY™ and GEN3013. Since the safety and tolerability of...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in e...

Enrolling
DLBCL
Diffuse Large B Cell Lymphoma
Drug: R-pola-mini-CHP
Drug: R-mini-CHOP

The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.

Enrolling
Solid Tumors
Drug: Bemarituzumab

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combin...

Active, not recruiting
Advanced Solid Tumors Cancer
Drug: Osimertinib
Drug: Nivolumab

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Enrolling
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodyspla...

Enrolling
Relapsed/Refractory AML
Myelodysplastic Syndromes
Drug: Venetoclax
Drug: Bexmarilimab

This study is open to children and adolescents with interstitial lung disease (ILD) that causes lung fibrosis. This is a study for people who took pa...

Active, not recruiting
Lung Diseases, Interstitial
Drug: Nintedanib (Ofev®)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatmen...

Enrolling
Metastatic Cholangiocarcinoma
Unresectable Cholangiocarcinoma
Drug: Cisplatin
Drug: Gemcitabine

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: Placebo
Drug: BI 1015550

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL).Acalabrutinib...

Active, not recruiting
MCL
Mantle Cell Lymphoma
Drug: Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma

The purpose is to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the I...

Enrolling
Metastatic Breast Cancer
Drug: Ixabepilone Injection

To assess:efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification,...

Enrolling
Glioblastoma Multiforme
Brain Tumor
Drug: APL-101 Oral Capsules

This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemot...

Active, not recruiting
Recurrent Ovarian Carcinoma
Drug: Bevacizumab
Drug: Chemotherapy

This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not...

Active, not recruiting
Liposarcoma, Dedifferentiated
Drug: Brigimadlin (BI 907828)
Drug: Doxorubicin

The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage II...

Active, not recruiting
NSCLC, Stage III
Non Small Cell Lung Cancer
Drug: Durvalumab Injection

Trial sponsors

T

Tampere University Hospital (119 trials)

Boehringer Ingelheim logo

Boehringer Ingelheim (11 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems